insulin detemir vs Insulin glargine (Basaglar)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

insulin detemir · Levemir

Rights held by Novo Nordisk; US product discontinued

Approved in Type 2 Diabetespeptide
Partial signal

NCT00283751 · Phase 3 · completed

The study randomized 583 participants to insulin detemir or insulin glargine, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07) (met)

Result source: NCT00856986

Insulin glargine (Basaglar)

Marketed by Eli Lilly and partners

Approved in Type 2 Diabetespeptide
Partial signal

NCT01421459 · Phase 3 · completed

The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)

Result source: NCT03338010

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin detemirInsulin glargine (Basaglar)
HbA1c, change-0.5% vs 0.0%vs Lira 1.8wk 26 · n 160NCT00856986
6 other results
  • -0.5% vs -0.1% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -0.5% vs 0.0% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs -0.7% wk 26 · n 209 · Phase 4 · primary NCT00909480
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459
Body weight, change (kg)3.6 vs 6.4vs Insulin Aspartwk 156 · n 234NCT00184600
8 other results
  • -0.1 vs -1.0 wk 52 · n 162 · Phase 3 · secondary NCT00856986
  • 1.9 vs 5.7 wk 52 · n 234 · Phase 3 · secondary NCT00184600
  • -0.2 vs -0.9 wk 26 · n 162 · Phase 3 · secondary NCT00856986
  • -0.8 vs -1.7 wk 26 · n 103 · Phase 3 · secondary NCT00789191
  • -0.5 vs 1 wk 26 · n 196 · Phase 4 · secondary NCT00909480
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 13 vs 12.6 n 45 · Phase na · secondary NCT01837680
  • 1.2 vs 2.8 Phase 3 · primary NCT00604396
1.9 vs 2.2vs Lantuswk 24 · n 370NCT01421459
7 other results
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.6 vs 1.9 wk 16 · n 370 · Phase 3 · secondary NCT01421459
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459
HbA1c below 7%—Not posted · NCT0060439643.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010
Fasting plasma glucose, change-1.9 vs -0.1vs Lira 1.8wk 52 · n 160NCT00856986
2 other results
  • -2.1 vs -0.4 wk 26 · n 160 · Phase 3 · secondary NCT00856986
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
—Not reported
3-point MACE (% with event)—Not posted · NCT00604396—Not reported

HbA1c, change

insulin detemir
-0.5% vs 0.0%vs Lira 1.8wk 26 · n 160NCT00856986
6 other results
  • -0.5% vs -0.1% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -0.5% vs 0.0% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs -0.7% wk 26 · n 209 · Phase 4 · primary NCT00909480
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
Insulin glargine (Basaglar)
-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459

Body weight, change (kg)

insulin detemir
3.6 vs 6.4vs Insulin Aspartwk 156 · n 234NCT00184600
8 other results
  • -0.1 vs -1.0 wk 52 · n 162 · Phase 3 · secondary NCT00856986
  • 1.9 vs 5.7 wk 52 · n 234 · Phase 3 · secondary NCT00184600
  • -0.2 vs -0.9 wk 26 · n 162 · Phase 3 · secondary NCT00856986
  • -0.8 vs -1.7 wk 26 · n 103 · Phase 3 · secondary NCT00789191
  • -0.5 vs 1 wk 26 · n 196 · Phase 4 · secondary NCT00909480
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 13 vs 12.6 n 45 · Phase na · secondary NCT01837680
  • 1.2 vs 2.8 Phase 3 · primary NCT00604396
Insulin glargine (Basaglar)
1.9 vs 2.2vs Lantuswk 24 · n 370NCT01421459
7 other results
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.6 vs 1.9 wk 16 · n 370 · Phase 3 · secondary NCT01421459
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459

HbA1c below 7%

insulin detemir
—Not posted · NCT00604396
Insulin glargine (Basaglar)
43.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010

Fasting plasma glucose, change

insulin detemir
-1.9 vs -0.1vs Lira 1.8wk 52 · n 160NCT00856986
2 other results
  • -2.1 vs -0.4 wk 26 · n 160 · Phase 3 · secondary NCT00856986
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
Insulin glargine (Basaglar)
—Not reported

3-point MACE (% with event)

insulin detemir
—Not posted · NCT00604396
Insulin glargine (Basaglar)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. insulin detemir: 6 of 6 rows · Insulin glargine (Basaglar): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin detemir
Rows use multiple source trials
Insulin glargine (Basaglar)
Rows use multiple source trials
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.9% (n=21) @ 12wka,b,c
NCT01868542 · Phase 4 · registry result, not featured evidence
show 1 more dose
-0.8% (n=23) @ 12wk
NCT01868542 · Phase 4 · registry result, not featured evidence
-0.641% (n=259) @ 12wkb,c
NCT04153981 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5
responder rate · % of participants
43.2% (n=234) vs 44.8% (n=239) Insulin Aspart @ 156wkb,c,d
NCT00184600 · Phase 3 · registry result, not featured evidence
23.4% (n=334) vs 16.5% (n=158) Lantus® @ 24wkb,c,d
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Dropout rate
0%e
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
8.7%Insulin Detemir (2-4-6-8 Algorithm
NCT01868542 · Phase 4 · registry result, not featured evidence
0%Insulin Detemir (3-0-3 Algorithm )
NCT01868542 · Phase 4 · registry result, not featured evidence
13.9%
NCT01165684 · Phase 4 · registry result, not featured evidence
16.7%
NCT00909480 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
6.9%
NCT00455858 · Phase 4 · registry result, not featured evidence
12.3%FPG 70-90 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
14.8%FPG 80-110 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00590226 · Phase 4 · registry result, not featured evidence · combination
19.2%
NCT00184600 · Phase 3 · registry result, not featured evidence
12.6%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
0%Iiraglutide
NCT01232946 · Phase na · registry result, not featured evidence
18.2%Liraglutide Plus Insulin Detemir
NCT01232946 · Phase na · registry result, not featured evidence · combination
15.1%
NCT01837680 · Phase na · registry result, not featured evidence
11.9%f
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
7.6%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.4%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
28.3%
NCT04153981 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
0%e
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—Insulin Detemir (2-4-6-8 Algorithm
NCT01868542 · Phase 4 · registry result, not featured evidence
—Insulin Detemir (3-0-3 Algorithm )
NCT01868542 · Phase 4 · registry result, not featured evidence
0.5%
NCT01165684 · Phase 4 · registry result, not featured evidence
2.2%
NCT00909480 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
—
NCT00591227 · Phase 4 · registry result, not featured evidence
—
NCT00455858 · Phase 4 · registry result, not featured evidence
1.6%FPG 70-90 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
2.5%FPG 80-110 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
—
NCT00590226 · Phase 4 · registry result, not featured evidence · combination
3.8%
NCT00184600 · Phase 3 · registry result, not featured evidence
1.8%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
—Iiraglutide
NCT01232946 · Phase na · registry result, not featured evidence
—Liraglutide Plus Insulin Detemir
NCT01232946 · Phase na · registry result, not featured evidence · combination
—
NCT01837680 · Phase na · registry result, not featured evidence
1.6%f
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
0.4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT04153981 · Phase 4 · registry result, not featured evidence
Serious AEs
10.4%e
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
4.3%Insulin Detemir (2-4-6-8 Algorithm
NCT01868542 · Phase 4 · registry result, not featured evidence
0%Insulin Detemir (3-0-3 Algorithm )
NCT01868542 · Phase 4 · registry result, not featured evidence
9.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
3.1%
NCT00909480 · Phase 4 · registry result, not featured evidence
0%
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
5.7%
NCT00455858 · Phase 4 · registry result, not featured evidence
4.1%FPG 70-90 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
3.3%FPG 80-110 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
0%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
22.4%
NCT00590226 · Phase 4 · registry result, not featured evidence · combination
33.3%
NCT00184600 · Phase 3 · registry result, not featured evidence
1.9%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
0%Iiraglutide
NCT01232946 · Phase na · registry result, not featured evidence
0%Liraglutide Plus Insulin Detemir
NCT01232946 · Phase na · registry result, not featured evidence · combination
0%
NCT01837680 · Phase na · registry result, not featured evidence
4%f
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
e
nasopharyngitis 20.2%
nausea 18.4%
diarrhoea 17.8%
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 13 more results
nasopharyngitis 13%
headache 8.7%
upper respiratory tract infection 4.3%
NCT01868542 · Phase 4 · registry result, not featured evidence
nasopharyngitis 13%
rash 8.7%
upper respiratory tract infection 8.7%
NCT01868542 · Phase 4 · registry result, not featured evidence
nasopharyngitis 8.1%
headache 5.1%
influenza 5.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
nasopharyngitis 10.6%
upper respiratory tract infection 8%
headache 7.5%
NCT00909480 · Phase 4 · registry result, not featured evidence
nasopharyngitis 11.5%
upper respiratory tract infection 5.7%
NCT00455858 · Phase 4 · registry result, not featured evidence
back pain 5.8%
headache 5%
upper respiratory tract infection 5%
NCT00634842 · Phase 4 · registry result, not featured evidence
pain in extremity 3.3%
urinary tract infection 3.3%
anxiety 2.5%
NCT00634842 · Phase 4 · registry result, not featured evidence
nausea 11.1%
diarrhoea 5.6%
hypertension 5.6%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 46.2%
diarrhoea 25.6%
infection 21.4%
NCT00184600 · Phase 3 · registry result, not featured evidence
headache 14.5%
nasopharyngitis 13.2%
back pain 10.5%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
gastrointestinal intolerance 0%
NCT01232946 · Phase na · registry result, not featured evidence
gastrointestinal intolerance 18.2%
NCT01232946 · Phase na · registry result, not featured evidence · combination
biochemical event of hypoglycemia 50.9%
symptomatic hypoglycemia 30.2%
symptomatic nocturnal event 15.1%
NCT01837680 · Phase na · registry result, not featured evidence
f
nasopharyngitis 5.6%
upper respiratory tract infection 5.1%
abnormal weight gain 2.7%
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
nasopharyngitis 7.2%
upper respiratory tract infection 4%
weight increased 3.2%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
upper respiratory tract infection 20.3%
hypertension 5.6%
injection site pain 4.2%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
anaemia 1.9%
cough 0.4%
hyperglycaemia 0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 156 weeks versus 24 weeks.
  5. ePopulation comparability has not been reviewed for 16 of these studies.
  6. fPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin detemir

Fasting Plasma Glucose -2.12 vs -0.39 Lira 1.8 mmol/L @ 26wk
absolute change · mmol/L
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-1.91 vs -0.14 Lira 1.8 mmol/L @ 52wk
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
NA vs 5.83 Insulin Detemir mmol/L @ 13wk
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
6.44 vs 4.94 Insulin Detemir mmol/L @ 26wk*
NCT00998335 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 116 mg/dL as posted
Waist Circumference Change -0.78 vs -0.66 Lira 1.8 cm @ 26wk
absolute change · cm
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
Waist Circumference Change -0.83% (n=160) vs -0.83% (n=148) Lira 1.8 @ 52wk
absolute change · percentage points
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Plasma Glucose -4.12 mmol/L @ 12wk
absolute change · mmol/L
No placebo or comparator arm
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -74.3 mg/dL as posted
show 3 more results
-2.48 mmol/L @ 12wk*
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -44.6 mg/dL as posted
-3.35 mmol/L @ 20wk*
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -60.4 mg/dL as posted
-3.89 mmol/L @ 20wk*
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -70 mg/dL as posted
HbA1c Less Than 7 19.2% (n=193) vs 56.3% (n=183) insulin aspart @ 10wk
absolute value · percentage points
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
45.1% (n=195) vs 65.4% (n=188) insulin aspart @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
55.9% (n=195) vs 63.3% (n=188) insulin aspart @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose 7.1 vs 6.7 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 5 more results
7.1 vs 7 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
7.12 vs 7.01 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
6.22 vs 6.09 IGlar mmol/L @ 26wk
NCT00909480 · Phase 4 · registry result, not featured evidence
6.08 vs 8.52 Sitagliptin mmol/L @ 26wk
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
5.4 vs 5.59 Insulin NPH mmol/L*
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 97.3 mg/dL as posted
Postprandial Glucose Increment 2.3 vs 1.4 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
1.9 vs 1.5 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
1.64 vs 1.28 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Body Weight 89.32 vs 89.8 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
BMI 31.86 vs 32.03 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
HbA1c 7 0 or Less 38% (n=209) vs 53% (n=204) IGlar @ 26wk
responder rate · % of participants
All
NCT00909480 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7 Without Hypoglycemia 32% (n=209) vs 38% (n=204) IGlar @ 26wk
absolute value · percentage points
All
NCT00909480 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6 5 11% (n=209) vs 21% (n=204) IGlar @ 26wk
absolute value · percentage points
All
NCT00909480 · Phase 4 · registry result, not featured evidence

+ 32 further endpoints in the CSV export.

Insulin glargine (Basaglar)

HbA1c Less Than 7% 43.7% (n=334) vs 44.9% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Weight -0.5 kg @ 24wk
absolute change · kg
No placebo or comparator arm
NCT04153981 · Phase 4 · registry result, not featured evidence
SMBG 7-point Change mg/dL -38.7 mg @ 24wk
absolute change · mg
No placebo or comparator arm
Blood glucose concentration before breakfast
NCT04153981 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin detemir's landscape · Insulin glargine (Basaglar)'s landscape